|
1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea |
|---|---|
| Trade Name | |
| Orphan Indication | Acute myeloid leukemia |
| USA Market Approval | USA |
| USA Designation Date | 2009-11-12 00:00:00 |
| Sponsor | Astex Therapeutics Ltd;436 Cambridge Science Park, CB4 0QA; |
